Notably, even when treatment was delayed after the injection of the HER2- expressing B16 melanoma cells, there was still 60% less metastatic invasion in the α-GalCer/sCD1d–anti-HER2 treated mice than in controls or α-GalCer-only treated animals. Here, ERBB2 is linked to melanoma.